Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PYXS
PYXS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PYXS News
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
Jan 12 2026
Newsfilter
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
Jan 08 2026
NASDAQ.COM
Experts Raise Concerns About Pyxis Oncology's Small Clinical Trial
Dec 19 2025
Benzinga
Tesla's Price Target of $444? Check Out 10 Leading Analyst Predictions for Friday
Dec 19 2025
Benzinga
Nasdaq Rises More Than 200 Points as US Inflation Decreases to 2.7%
Dec 18 2025
Benzinga
Dow Rises 400 Points as Accenture Reports Stronger-Than-Expected Earnings
Dec 18 2025
Benzinga
Pyxis Oncology Reports 46% ORR for MICVO Monotherapy in R/M HNSCC
Dec 18 2025
Globenewswire
Pyxis Oncology Reports 46% ORR for MICVO Monotherapy in R/M HNSCC
Dec 18 2025
Newsfilter
Pyxis Shares Drop After Phase 1 Results for Head and Neck Cancer Treatment Candidate
Dec 18 2025
SeekingAlpha
Pyxis Oncology to Showcase Translational Data and Important Biological Insights on MICVO's Mechanism of Action at Upcoming Medical Conferences
Oct 13 2025
Newsfilter
Pyxis Oncology Names Alex Kane as Senior Vice President of Investor Relations and Capital Markets
Oct 09 2025
Newsfilter
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 30 2025
Newsfilter
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
May 19 2025
Benzinga
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Apr 02 2025
Newsfilter
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Mar 25 2025
Newsfilter
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)
Mar 19 2025
Business Insider
Show More News
